The goal of HRSA-22-068 is to establish regional networks of hemophilia treatment centers (HTCs) to improve the health and well-being for children, youth, and adults with hemophilia and related bleeding disorders and clotting disorders.
HRSA will fund up to eight recipients will be funded for HRSA-22-068, one recipient per region. The eight HRSA-designated Hemophilia Regions1 are:
• New England: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Puerto Rico, US Virgin Islands
• Mid-Atlantic: Delaware, DC, Maryland, Pennsylvania, Virginia, West Virginia
• Southeast: Alabama, Florida, Georgia, Mississippi, Kentucky, North Carolina, South Carolina, Tennessee
• Great Lakes: Indiana, Michigan, Ohio
• Northern States: Illinois, Minnesota, North Dakota, South Dakota, Wisconsin
• Great Plains: Arkansas, Louisiana, Oklahoma, Texas, Iowa, Kansas, Missouri, Nebraska
• Mountain States: Alaska, Idaho, Oregon, Washington, Arizona, Colorado, Montana, New Mexico, Utah, Wyoming
• Western States and Territory: California, Hawaii, Nevada, and the Pacific Islands
1 The Hemophilia Regions are defined by HRSA using a combination of the Public Health Service Regions and similarity in numbers of patients and numbers of hemophilia treatment centers.
Each recipient is expected to be responsible for identifying, establishing, and monitoring a network of HTCs in the region. In collaboration with the NHPCC, recipients are expected to provide monitoring oversight, technical assistance (TA), education, and quality improvement opportunities for HTC staff on staff development issues, best practices for disease management and evidence-informed treatment guidelines, and patient and family education.
